Budge brings 25 years of CFO experience across a range of public and private high-growth technology companies.
In this role, he will be responsible for the company's financial strategy, driving quarterly performance, and stewarding sustainable growth to make high-quality care more accessible and affordable.
Budge joins Hinge Health at a time of unprecedented momentum. Following the company's strong Series E funding, Hinge Health published the largest medical claims analysis ever performed for a digital musculoskeletal (MSK) solution, showing a 2.4x ROI, and surpassed its 1,000 enterprise customer milestone – closing more new customers in 2022 than the prior 7 years combined.
Strategic acquisitions, including Enso and wrnch, further established Hinge Health's technology portfolio as the most advanced in the industry, able to deliver the market's leading member experience and strongest outcomes.
Budge most recently served as CFO of Automation Anywhere, where he led the company's efforts toward profitability.
His career has centered on serving as CFO to accelerate growth for public and late-stage private companies.
Over his career, he has raised billions in capital, taken multiple companies public, overseen dozens of acquisitions, and led numerous efforts to improve critical infrastructure. Budge holds a bachelor's in accounting from Brigham Young University and currently sits on the board of Shadowbox.
Hinge Health pairs advanced motion technology and wearable pain relief with a complete clinical care team of physical therapists, physicians, and board-certified health coaches to help people move beyond pain and reduce surgeries and opioid use.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer